Drug Profile
AZD 1390
Alternative Names: [11C]-AZD1390; AZD1390; Radiolabeled AZD-1390Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Mayo Clinic
- Class Antineoplastics; Radiosensitisers; Small molecules
- Mechanism of Action Ataxia telangiectasia mutated protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Glioblastoma; Soft tissue sarcoma; Solid tumours
- Preclinical Breast cancer; Meningioma
- No development reported Cancer; Non-small cell lung cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(In the elderly, Late-stage disease, In adults) in United Kingdom (PO, Tablet)
- 07 Dec 2023 Efficacy data from an early phase I trial in Glioblastoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Metastatic disease, Recurrent) in United Kingdom (IV, Injection)